Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study
Article Abstract:
Tissue-type plasminogen activator (t-PA) may be beneficial for treating stroke. t-PA breaks up blood clots, which are the cause of most strokes. Researchers gave 389 patients with the symptoms of a stroke intravenous alteplase. Alteplase is a synthetic form of tPA. Thirty days after their stroke, 35% of the patients were doing well and 43% were capable of taking care of themselves. Eight percent had bleeding in their brain, which is a side effect of t-PA.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: The Cleveland Area Experience
Article Abstract:
Tissue-type plasminogen activator (tPA) may not benefit many stroke patients. tPA breaks down blood clots, which cause most strokes. Of 3,948 patients admitted to a hospital with symptoms of a stroke, 70 received tPA. Eleven developed bleeding in the brain, which killed six. Bleeding in the brain is a known complication of tPA treatment. Sixteen percent of the patients who received tPA died, compared to 8% of those who did not receive tPA.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset: The ATLANTIS Study: A Randomized Controlled Trial
Article Abstract:
Recombinant tissue-type plasminogen activator (rt-PA) does not appear to improve the outcome of stroke patients when given more than 3 hours after the stroke began. Researchers randomly assigned 547 stroke patients to receive a one-hour intravenous infusion of rt-PA or a placebo between 3 to 5 hours after the stroke began. About one-third of both groups had recovered three months later. Patients who received rt-PA were more likely to develop bleeding in the brain and more likely to die within three months compared to those who received a placebo, or inactive substance.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: A randomized controlled trial
- Abstracts: Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection: Two Randomized Controlled Trials
- Abstracts: Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. Trends in the Prescribing of Psychotropic Medications to Preschoolers
- Abstracts: Impaired activity of protease inhibitors towards neutrophil elastase bound to human articular cartilage. Cyclopentenone prostaglandins -- new allies in the war on inflammation
- Abstracts: The dental unit waterline controversy: defusing the myths, defining the solution. Dental unit waterline antimicrobial agents' effect on dentin bond strength